| Autor: |
Coan, P. C., Joubert, Romain, Walker, Zoe, Dellow, Emily, Sheikh, Nadia, Reilly, Louise, Andreassi, Catia, Brock, Olivier, Nafchi, N. A. M., Abhilash, Amrita, Ireland, Lydia, Miranda, C. J., Isaac, John, Lee, D. Y., Lee, Y. B., Shaw, Chris E., Akerman, S. Can, Spead, Olivia, Huang, Meixiang, Thomas, Ajit G. |
| Předmět: |
|
| Zdroj: |
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration; 2024 Suppl 1, Vol. 25, p197-217, 21p |
| Abstrakt: |
The document delves into pre-clinical therapeutic strategies for amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD), focusing on targeting specific proteins like Atxn2, TDP-43, and FUS for potential gene therapies and small molecules. It also examines the role of sphingolipids, mitochondrial dysfunction, and immune responses in ALS pathogenesis, offering potential therapeutic interventions. Additionally, the document explores the impact of ketogenic diets, regulatory T cells, and HERV-K ENV protein on ALS progression, providing a comprehensive overview of diverse therapeutic approaches for ALS and FTD. Various research studies in the document explore treatments for ALS, including antibodies targeting TDP-43, gene silencing approaches, AAV-mediated gene therapies, and the therapeutic effects of probiotics and remote ischemic conditioning in ALS models. Other studies investigate neuronal excitability modulation through transcranial magnetic stimulation and the potential neuroprotective effects of Lactocaseibacillus rhamnosus HA-114, aiming to offer novel therapeutic strategies for ALS. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
